Editorial| Volume 9, SUPPLEMENT 1, S1-S3, September 2016

Time and brain health both matter in multiple sclerosis

      The wide global variation in the diagnosis and management of multiple sclerosis (MS) underpins the need for consensus in the field and provides the backdrop for the development of a policy. When our global, multidisciplinary group first met to draft a consensus report, or policy, on MS, we all agreed that ‘Time matters’ in the treatment and management of this disease. We should be aiming to maximize the lifelong brain health of people with MS through early diagnosis, early treatment, proactively monitoring and recording disease activity, treating to a target with an appropriate disease-modifying therapy (DMT), incorporating shared decision-making and adopting an holistic approach to the management of MS (Fig. 1).
      Fig. 1
      Fig. 1We recommend a therapeutic strategy that aims to preserve CNS tissue and maximize lifelong neurological reserve (an important component of brain health) by minimizing disease activity. (CNS, central nervous system; DMT, disease-modifying therapy).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Glanz B.I.
        • Healy B.C.
        • Rintell D.J.
        • Jaffin S.K.
        • Bakshi R.
        • Weiner H.L.
        The association between cognitive impairment and quality of life in patients with early multiple sclerosis.
        J. Neurol. Sci. 2010; 290: 75-79
        • Kalincik T.
        • Vaneckova M.
        • Tyblova M.
        • Krasensky J.
        • Seidl Z.
        • Havrdova E.
        • et al.
        Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.
        PLoS One. 2012; 7: e50101
        • Kappus N.
        • Weinstock-Guttman B.
        • Hagemeier J.
        • Kennedy C.
        • Melia R.
        • Carl E.
        • et al.
        Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 181-187
        • Marrie R.A.
        • Rudick R.
        • Horwitz R.
        • Cutter G.
        • Tyry T.
        • Campagnolo D.
        • et al.
        Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.
        Neurology. 2010; 74: 1041-1047
      1. MS Brain Health. About us. MS Brain Health; 2016a. (accessed 15.07.16. at: 〈〉).

      2. MS Brain Health, 2016b. Brain health: time matters in multiple sclerosis – slide deck for presentation to healthcare professionals. MS Brain Health 2016b. (accessed 27.06.16. at: 〈〉).

      3. MS Brain Health, 2016c. Brain health: a guide for people with multiple sclerosis – slide deck for presentation to people with MS. MS Brain Health 2016c. (accessed 15.07.16. at: 〈〉).

        • Popescu V.
        • Agosta F.
        • Hulst H.E.
        • Sluimer I.C.
        • Knol D.L.
        • Sormani M.P.
        • et al.
        Brain atrophy and lesion load predict long term disability in multiple sclerosis.
        J. Neurol. Neurosurg. Psychiatry. 2013; 84: 1082-1091
        • Radue E.W.
        • Barkhof F.
        • Kappos L.
        • Sprenger T.
        • Haring D.A.
        • de Vera A.
        • et al.
        Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
        Neurology. 2015; 84: 784-793
        • Rao S.M.
        • Leo G.J.
        • Ellington L.
        • Nauertz T.
        • Bernardin L.
        • Unverzagt F.
        Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning.
        Neurology. 1991; 41: 692-696
        • Rocca M.A.
        • Filippi M.
        Functional MRI in multiple sclerosis.
        J. Neuroimaging. 2007; 17: S36-S41
        • Rocca M.A.
        • Mezzapesa D.M.
        • Falini A.
        • Ghezzi A.
        • Martinelli V.
        • Scotti G.
        • et al.
        Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis.
        NeuroImage. 2003; 18: 847-855
        • Schwartz C.E.
        • Quaranto B.R.
        • Healy B.C.
        • Benedict R.H.
        • Vollmer T.L.
        Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?.
        Arch. Phys. Med. Rehabil. 2013; 94: 1971-1981
        • Sormani M.P.
        • Arnold D.L.
        • De Stefano N.
        Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.
        Ann. Neurol. 2014; 75: 43-49
        • Stern Y.
        What is cognitive reserve? Theory and research application of the reserve concept.
        J. Int. Neuropsychol. Soc. JINS. 2002; 8: 448-460
        • Sumowski J.F.
        • Rocca M.A.
        • Leavitt V.M.
        • Riccitelli G.
        • Comi G.
        • DeLuca J.
        • et al.
        Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it.
        Neurology. 2013; 80: 2186-2193
        • Tettey P.
        • Simpson Jr., S.
        • Taylor B.V.
        • van der Mei I.A.
        Vascular comorbidities in the onset and progression of multiple sclerosis.
        J. Neurol. Sci. 2014; 347: 23-33
        • Uher T.
        • Horakova D.
        • Bergsland N.
        • Tyblova M.
        • Ramasamy D.P.
        • Seidl Z.
        • et al.
        MRI correlates of disability progression in patients with CIS over 48 months.
        NeuroImage: Clin. 2014; 6: 312-319